Neuren Pharmaceuticals and its US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue.

Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key ...

Investing in real estate is a cornerstone of wealth for a majority of Aussies, but before getting started you should ask yourself this.

Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs you should have in your portfolio.

The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle ...

ASX gold explorer Arika is chasing more elephants in the elephant country of Laverton in WA's Goldfields. And the market is ...

So, are we looking at a crash or a V-shaped recovery? Learn the six things every investor should probably know.

Trump’s tariffs are shaking things up worldwide, but small cap Aussie utilities might just sail through and even come out ...

Finder Energy has flagged just how serious Timor Leste is about attracting resource investment and why it stands out from the ...

ASX jumps on tariff relief, Wall Street ends strongly despite "Sell America" talk and Neuren and GGE take off.

Koonenberry Gold has lifted 30% on broad, high-grade results from the second diamond hole at Sunnyside prospect.

ASX climbs on the back of resource stocks as miners gain. Gold hovers at record highs as US and Asian stocks post weekly gains ...